N
47.60
0.30 (0.63%)
| Previous Close | 47.30 |
| Open | 46.75 |
| Volume | 17,357 |
| Avg. Volume (3M) | 123,681 |
| Market Cap | 33,618,072 |
| Price / Sales | 1.73 |
| Price / Book | 0.710 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 |
| Profit Margin | -212.72% |
| Operating Margin (TTM) | -84.87% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 209.10% |
| Total Debt/Equity (MRQ) | 24.81% |
| Current Ratio (MRQ) | 6.33 |
| Operating Cash Flow (TTM) | -9.82 M |
| Levered Free Cash Flow (TTM) | -13.66 M |
| Return on Assets (TTM) | -10.19% |
| Return on Equity (TTM) | -57.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (GB) | Mixed | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | NOVACYT S.A. EUR1/15TH (CDI) | - | - |
AIStockmoo Score
0.9
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| NOVACYT S.A. EUR1/15TH (CDI) | 34 M | - | - | 0.710 |
| 0K5E | 765 M | 4.01% | 7.06 | - |
| MAXCYTE INC COM STK USD0.01 (DI | 202 M | - | - | 1.43 |
| CREO MEDICAL GROUP PLC ORD GBP0 | 44 M | - | - | 1.57 |
| INTELLIGENT ULTRASOUND GROUP PL | 36 M | - | - | 7.29 |
| INSPIRATION HEALTHCARE GROUP PL | 15 M | - | - | 0.550 |
|
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 0.05% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |